Skip to main content
. 2022 Apr 2;10(6):1622–1634.e4. doi: 10.1016/j.jaip.2022.03.017

Figure 1.

Figure 1

SARS-CoV-2 anti-spike antibody levels (U/mL), shown in log scale and compared between matched healthy controls (HC) (gray squares; n = 62) and patients with predominant antibody deficiency (PAD) (red circles; n = 62). Shown by all vaccine types (A) and by specific initial series SARS-CoV-2 vaccine type received (B, C). Symbols represent unique individuals, bars represent geometric means (±95% confidence intervals) of total indicated patients (n), and shading represents the assay lower limit of reactivity. ∗P < .05; ∗∗P < .01.